medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.

David J Sullivan[1] Massimo Franchini[2], Michael J. Joyner[3], Arturo Casadevall[1], Daniele Focosi[4,#],

[1]Johns Hopkins Bloomberg School of Public Health and School of Medicine, Baltimore, MD 21218, USA; dsulliv7@jhmi.edu, acasade1@jhu.edu,

[2]Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy; massimo.franchini@asst-mantova.it

[3]Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, MN 55902, USA joyner.michael@mayo.edu ;

[4]North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.

[#]corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: daniele.focosi@gmail.com .

Keywords: COVID19; Omicron; convalescent plasma; vaccine; neutralizing antibodies.

Word count: abstract 220; body 2979.

Acknowledgements: none.

Funding Information: The analysis was supported by the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012) (D.S), with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) 3R01AI152078-01S1) (A.C).

Author contributions: D.F. and M.J.J. conceived the manuscript; D.F., D.J.S. and M.F. analyzed the literature, curated tables and wrote manuscripts; M.F. provided Figure 1; D.J.S. provided Figures 2 -5.A.C. and M.J.J. revised the manuscript.

Data availability statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

The latest SARS-CoV-2 variant of concern Omicron, with its immune escape from therapeutic anti-Spike monoclonal antibodies and WA-1 vaccine-elicited sera, demonstrates the continued relevance of COVID-19 convalescent plasma (CCP) therapies. Lessons learnt from previous usage of CCP suggests focusing on early outpatients and immunocompromised recipients, with high neutralizing antibody (nAb) titer units. In this analysis we systematically reviewed Omicron-neutralizing plasma activity data, and found that approximately 47% (424/902) of CCP from unvaccinated pre-Omicron donors neutralizes Omicron BA.1 with a very low geomean of geometric mean titers for 50% neutralization GM(GMT_{50}) of about 13, representing a more than 20-fold reduction from WA-1 neutralization. Two doses of mRNA vaccines in nonconvalescent subjects had a similar 50% percent neutralization with Omicron BA.1 neutralization GM($GMT_{(50)}$) of about 27. However, plasma from vaccinees recovered from either previous pre-Omicron variants of concern infection, Omicron BA.1 infection, or third-dose uninfected vaccinees was nearly 100% neutralizing against Omicron BA.1, BA.2 and BA.4/5 with GM($GMT_{(50)}$) all over 189, 10 times higher than pre-Omicron CCP. Fully vaccinated and post-BA.1 plasma (Vax-CCP) had GM(GMT_{50}) over 450 for BA.4/5 and over 1500 for BA.1 and BA.2. These findings have implications for both CCP stocks collected in prior pandemic periods and plans to restart CCP collections. Thus, Vax-CCP provides an effective tool to combat ongoing variants that defeat therapeutic monoclonal antibodies.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

The SARS-CoV-2 Omicron variant of concern (VOC) (originally named VUI-21NOV-01 by Public Health England and belonging to GISAID clade GRA(B.1.1.529+BA.*) was first reported on November 8, 2021 in South Africa, and shortly thereafter was also detected all around the world. Omicron mutations impact 27% of T cell epitopes [1] and 31% of B cell epitopes of the Spike protein, while percentages for other VOC were much lower [2]. The Omicron variant has further evolved to several sublineages which are named by PANGO phylogeny using the BA alias: the BA.1 wave of Winter 2021-2022 has been suddenly replaced by BA.2 and BA.2.12.1 in Spring 2022, and by the BA.4 and BA.5 waves in Summer 2022.

The VOC Omicron is reducing the efficacy of all vaccines approved to date (unless 3 doses are delivered) and is initiating an unexpected boost in COVID19 convalescent plasma (CCP) usage, with Omicron being treated as a shifted novel virus instead of a SARS-CoV-2 variant drift. Two years into the pandemics, we are back to the starting line for some therapeutic classes. Specifically, Omicron escapes viral neutralization by most monoclonal antibodies (mAbs) authorized to date with the lone exception of bebtelovimab [3]. Despite the development of promising oral small-molecule antivirals (molnupiravir and nirmatrelvir), the logistical and economical hurdles for deploying these drugs worldwide has prevented their immediate and widespread availability, and concerns remain regarding both molnupiravir (both safety[4] and efficacy [5]) and nirmatrelvir (efficacy), expecially in immunocompromised subjects. CCP was used as a frontline treatment from the very beginning of the pandemic. Efficacy outcomes have been mixed to date, with most failures explained by low dose, late usage, or both, but efficacy of high-titer CCP has been definitively proven in outpatients with mild disease stages [6, 7]. Neutralizing antibody (nAb) efficacy against VOC remains a prerequisite to support CCP usage, which can now be collected from vaccinated convalescents, including donors recovered from breakthrough infections (so-called “hybrid plasma” or “Vax-CCP”)[8]: pre-Omicron evidence suggest that those nAbs have higher titers and are more effective against VOCs than those from unvaccinated convalescents [9, 10]. From a regulatory viewpoint, to date, plasma from vaccinees that have never been convalescent does not fall within the FDA emergency use authorization

There are tens of different vaccine schedules theoretically possible according to EMA and FDA approvals, including a number of homologous or heterologous boosts, but the most commonly delivered schedules in the western hemisphere have been: 1) BNT162b2 or mRNA-1273 for 2 doses eventually followed by a homologous boost; 2) ChAdOx1 for 2 doses eventually followed by a BNT162b2 boost; and 3) Ad26.COV2.S for 1 dose eventually followed by a BNT162b2 boost [11]. Many more inactivated vaccines have been in use in low-and-middle income countries (LMIC), which are target regions for CCP therapy: this is feasible given the lower number of patients at risk for disease progression there (lower incidences of obesity, diabetes, and hypertension, and lower median age) and the already widespread occurrence of collection and transfusion facilities. Most blood donors there have already received the vaccine schedule before, after or without having been infected, with a nAb titer generally declining over months [12]. Hence identifying the settings where the nAb titer is highest will definitively increase the efficacy of CCP collections. Variations in nAb titers against a given SARS-CoV-2 strain are usually reported as fold-changes in geometric mean titer of antibodies neutralizing 50% of cytopathic effect (GMT_{50}) compared to wild-type strains: nevertheless, fold-changes for groups that include non-responders can lead to highly artificial results and possibly over-interpretation. Rigorous studies have hence reported the percentage of

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

responders as primary outcome and provided fold-changes of GMT_{50} where calculation is reasonable (100% responders in both arms) [13].

To date the most rigorous data repository for SARS-CoV-2 sensitivity to antivirals is the Stanford University Coronavirus Antiviral & Resistance Database, but as of July 24, 2022 the tables there summarizing "Convalescent plasma" and "Vaccinee plasma" (https://covdb.stanford.edu/search-drdb) do not dissect the different heterologous or homologous vaccination schemes, the simultaneous occurrence of vaccination and convalescence, or the time from infection/vaccine to neutralization assay. Consequently, a more in-depth analysis is needed to better stratify CCP types.

Methods

On August 11, 2022, we searched PubMed, medRxiv and bioRxiv for research investigating the efficacy of CCP (either from vaccinated or unvaccinated donors) against SARS-CoV-2 VOC Omicron (pre)published after December 1, 2019, using English language as the only restriction. In PubMed we used the search query "("convalescent plasma" or "convalescent serum") AND ("neutralization" or "neutralizing") AND "SARS-CoV-2"", while in bioRxiv and medRxiv we searched for abstract or title containing "convalescent, SARS-CoV-2, neutralization" (match all words). When a preprint was published, the latter was used for analysis. We also screened the reference lists of reviewed articles for additional studies not captured in our initial literature search. Articles underwent evaluation for inclusion by two assessors (D.F. and D.J.S.) and disagreements were resolved by a third senior assessor (A.C.). We excluded review articles, meta-analyses, studies reporting antibody levels by serological assays other than neutralization, as well as studies exclusively analyzing nAbs in vaccine-elicited plasma/serum from non-convalescent subjects. In unvaccinated subjects, convalescence was annotated according to infecting sublineage (pre-VOC Alpha, VOC Alpha, VOC Beta, VOC Delta, or VOC Omicron BA.1 sublineages). Given the heterologous immunity that develops after vaccination in convalescents, the infecting lineage was not annotated in vaccine recipients. In vaccinees, strata were created for 2 homologous doses, 3 homologous doses, or post-COVID-19 and post-vaccination (Vax-CCP). The type of viral assay (live or pseudovirus), time interval to blood sample, geometric mean, minimum and maximum neutralizing 50% dilutional titer for WA-1 (pre-Alpha wild-type) and Omicron sublineages BA.1, BA.2 and BA.4/5, and number out of total that neutralized Omicron was abstracted from study text, graphs and tables.

Statistical significance between $\log_{10}$ transformed geometric study means was investigated using Tukey's test.

Results

Our literature search identified 31 studies dealing with the original Omicron lineage (BA.1), that were then manually mined for relevant details: the PRISMA flowchart for study selection is provided in Figure 1. Given the urgency to assess efficacy against the upcoming VOC Omicron, many studies (with a few exceptions[14, 15, 16, 17]) relied on Omicron BA.1 pseudovirus neutralization assays, which, as opposed to live authentic virus neutralization assays, are scalable, do not require BSL-3 facilities, and provide results in

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

less than 1 week. Plasma dilutions were expressed in the studies as GMT_{50} of nAb, and fold-reduction in GMT_{50} compared to wild-type SARS-CoV-2 (e.g., WA-1) was the most common way of reporting changes, which reduces variability due to differences in the neutralization assays used. In comparing the large number of diverse studies with more than 100-fold plasma dilutional titers, we took the geometric mean of the individual study GMT_{50}, deriving a geomean of GMT_{50} (GM(GMT_{50})).

Figure 2 and Table 1 summarize that neutralizing activity to WA-1 from CCP collected from subjects infected with pre-Alpha SARS-CoV-2 (Supplementary Table 1), Alpha VOC (Supplementary Table 2), Beta VOC (Supplementary Table 3), Delta VOC (Supplementary Table 4) or plasma from nonconvalescent subjects vaccinated with 2 mRNA vaccine doses (Supplementary Tables 5 and 6). The same plasma types computed a geometric mean of multiple GMT_{50} from many studies with about a 20-fold reduction against BA.1 geomeans compared to wild-type SARS-CoV-2 geomeans. CCP from uninfected vaccinees receiving a third vaccine dose registered a geomean of the $GMT_{(50)}$ of 2,588 (or 10- fold higher nAb geomean of the GMT_{50}) to pre-alpha CCP viral assays. In this group the nAb geomean of the GMT_{50} fold-reduction against BA.1 was 9, but importantly the geomean of the $GMT_{(50)}$ was close to 300, similar to WA-1 inhibition by WA-1 CCP. The approximately 21-fold reduction in geomean of the $GMT_{(50)}$ from wild-type to BA.1 was reversed by the 10-15-fold increase in nAb geomean of the $GMT_{(50)}$ from either boosted (third-dose) vaccination or Vax-CCP.

In addition to the nAb GMT_{50} levels showing potency, the percentage of individuals within a study cohort positive for any level of BA.1 neutralization shows the likelihood of a possible donation having anti-BA.1 activity. All studies but one tested a limited number of 20 to 40 individuals. The pre-Alpha CCP showed that most (18 of 27 studies) had fewer than 50% of individuals tested within a study with measurable BA.1 neutralizing activity: only 2 out of 27 studies indicated that 100% of individuals tested showed BA.1 neutralization (Figure 3). Likewise, most of the studies investigating Alpha and Beta CCP showed similar percent with nAb. Delta CCP had 6 of 7 studies with more than 50% BA.1 neutralization. The plasma from studies of the 2-dose mRNA vaccines indicated a more uniform distributive increase in percent of individual patients with measurable Omicron BA.1 nAb's. The stark contrast is pre-Omicron Vax-CCP, where 14 of 17 studies had 100% of individuals tested with anti-BA.1 nAb. The 3-dose vaccinee studies similarly had 12 of 17 studies with 100% measurable nAb.

Five studies directly compared anti-WA-1 to BA.1 nAb titers in nonvaccinated pre-Alpha, Alpha, Beta, and Delta CCP, and vaccinated plasma with the same nAb assay (Figure 4). nAb GMT_{50} against WA-1 was higher for Alpha CCP but lower for Beta CCP. nAb geomean of the $GMT_{(50)}$ against BA.1 was actually highest for delta CCP with geomean levels of 6, 6, 10 for pre-Alpha, Alpha and Delta (Figure 4, panel A). In these 5 studies, nAb geomean of the $GMT_{(50)}$ rose from 2-dose vaccinations to Vax-CCP to the 3-dose boosted vaccination. Importantly, for nAb, geomean of the $GMT_{(50)}$ against BA.1 were 14 to 103 to 195, respectively (Figure 4, panel B).

Another set of 9 matched vaccination studies inclusive of plasma collected after 2- and 3-dose schedules, as well as Vax-CCP, depicted a 20-fold rise in the geomean of the $GMT_{(50)}$ of anti-BA.1 nAb from the 2-dose vaccine to post COVID-19 vaccinees, and a 21-fold increase after the third vaccine dose. The pattern was similar for nAb geomean of the $GMT_{(50)}$ against WA-1 (Figure 4, panel C).

The AZD1222, 3-dose mRNA-1273 and Ad26.COV2 vaccines were understudied, with 3 or less independent studies at different time points, reported in Table 10. The GMT_{50} nAb to BA.1 after 3-

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

mRNA-1273 doses ranged 60 to 2000, with a 5-to-15-fold reduction compared with WA-1. GMT_{50} of anti-BA.1 nAbs after AZD1222 vaccine was modest (~10 to 20), as with Ad26.COV2 vaccine (~20 to 40). Two studies reported on post-COVID-19/post-mRNA-1273 with nAb GMT_{50} against BA.1 of 38 and 272. Studies with 100% of individual patient samples neutralizing BA.1 included 2 3-dose mRNA-1273 studies, one AZD1222 study, and one post-COVID-19/post-mRNA-1273 study.

Few data exist for comparisons among different vaccine boosts. For CoronaVac® (SinoVac), three doses led to 5.1 fold reduction in anti-BA.1 nAb GMT_{50} compared to wild-type [18], while for Sputnik V nAb titer moved from a 12-fold reduction at 6-12 months up to a 7-fold reduction at 2-3 months after a boost with Sputnik Light [19, 20]. These *in vitro* findings have been largely confirmed *in vivo*, where prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination, protects against BA.1 re-infection [21].

Eleven studies analyzed the efficacy of CCP and Vax-CCP against Omicron sublineages other than BA.1, i.e. BA.2 and BA.4/5 (summarized in Table 2, Figure 5 and supplement Table 10, 11 and 12). Pre-Omicron (mainly Delta) CCP neutralized less than 40% of BA.1, BA.2 and BA.4/5. Unvaccinated individuals in 3 studies only with BA.1 primary infections poorly neutralized WA-1, with about 75% neutralizations of BA.1, BA.2 and BA.4/5. The 3 vaccine doses of BNT162b2 in 8 studies had a 7-, 6- and 16-fold reduction from WA-1 GM(GMT_{50}) of 3,247 with percent of neutralizations all over 95%. Individuals from 11 populations with a BA.1 VaxCCP had a 2-, 2- and 8-fold reduction for WA-1 GM(GMT_{50}) of 3578, with 99% Omicron neutralizations. Importantly, GM(GMT_{50}) of BA.1 Vax-CCP was more than 1.5 times higher than that of pre-alpha CCP for WA-1. Omicron BA.1, BA.2 and BA.4/5 percent neutralization was over 99% for each. In conclusion, BA.1-Vax- CCP was both high-titer and high neutralization percent.

These studies largely confirm that Omicron CCP *per se* is poorly effective against the cognate or other Omicron sublineages[22] (with the lone exception of cross-reactions among lineages sharing L452 mutations[23] and broad-spectrum nAbs elicited by BA.5[24]). By contrast, both the homologous and the heterologous efficacy of Omicron Vax-CCP is universally preserved [15, 25]. Despite evidence that concentrated pooled human IgGs from convalescent and vaccinated donors have 5-fold reduced potency against BA.5 compared to wild-type SARS-CoV-2 [26], such Vax-CCP derivative is devoid of IgA and IgM nAbs. These findings have important implications if a Vax-CCP program is to be re-launched at the time of BA.2 and BA.4/5 waves. In particular, the emerging R346X-harboring BA.4.6, BA.4.7, and BA.5.9 sublineages show 1.5-1.9-fold reduction in GMT_{50} by BA.1/2 Vax-CCP and 2.4-2.6 reduction by BA.5 Vax-CCP [27]. Of interest, Vax-CCP after 2 doses remains superior to 4-dose vaccinee plasma in terms of nAb titers, and Vax-CCP with 3 vaccine doses is not consistently superior to Vax-CCP after 2 vaccines doses[28].

Differences exist among neutralization assay protocols used across studies. These differences are placed in context once fold-reductions and percent neutralizations are used as reporting measures. The relative geometric mean titer with minimum and maximum titer levels is an alternative perspective. The live virus assays can be sorted from the pseudovirus assays along with the minimum and maximum extracted from the graphs or reported in data from the manuscripts. In general, about 80% of the live virus compared to pseudovirus overlap in dilutional titer magnitude with the pseudovirus assays outlier measurement consistently higher in range from a few studies (Figure 6). However, in some cases the minimum reported is not the limit of detection or quantification, but the lowest number in a group of SARS-CoV-2 antibody positive participants. Graphical depiction of the minimum and maximum dilutional titers are shown in Supplementary Figures 1-11.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Discussion

Since nAbs are by definition antiviral, CCP with a high nAb GMT_{50} is preferable, and there is now strong clinical evidence that nAb titers correlate with clinical benefit in randomized clinical trials[6, 7]. Although nAb titers correlate with vaccine efficacy[29, 30], it is important to keep in mind that SARS-CoV-2-binding non-neutralizing antibodies in CCP can similarly provide protection via Fc-mediated functions [31, 32]. However, such functions are harder to measure and no automated assay exists for use in clinical laboratories. Hence, whereas the presence of a high nAb GMT_{50} in CCP is evidence for antibody effectiveness *in vitro*, the absence of nAb titer does not imply lack of protection *in vivo* where Fc effects mediate protection by other mechanisms such as antibody-dependent cell-mediated cytotoxicity, complement activation and phagocytosis.

The mechanism by which CCP from vaccinated COVID-19 convalescent individuals better neutralizes Omicron lineages is probably a combination of higher amounts of nAb and broader antibody specificity. Higher amounts of antibody could neutralize antigenically different variants through the law of mass action [33], whereby even lower affinity antibodies elicited to earlier variants would bind to the Omicron variant as mass compensates for reduced binding strength to drive the reaction forward. In addition, vaccinated COVID-19 convalescent individuals would have experienced SARS-CoV-2 protein in two antigenically different forms: as part of intact infective virions generated *in vivo* during an infectious process and as antigens in vaccine preparations. As the immune system processes the same antigen in different forms, there are numerous opportunities for processing the protein in different ways that can diversify the specificity of the immune response and thus increase the likelihood of eliciting antibodies that react with variant proteins. Structurally, it has been shown that third dose mRNA vaccination induces mostly class 1/2 antibodies encoded by IGHV1-58;IGHJ3-1 and IGHV1-69;IGHJ4-1 germlines, but not the IGHV2-5;IGHJ3-1 germline, i.e. broadly cross-reactive Class 3 antibodies seen after infection [34].

Our analysis provides strong evidence that, unlike what has been observed in Syrian hamster models [35], CCP from unvaccinated donors is unlikely (less than 50%) to have any measurable Omicron neutralization. Although the nAb GMT_{50} threshold for clinical utility remains poorly defined, it is noticeable that low BA.1 nAb GMT_{50} were generally detected in CCP after infection from pre-Omicron VOCs.

However, despite the huge heterogeneity of vaccine schedules, CCP from vaccinated and COVID-19 convalescent individuals (Vax-CCP) consistently harbors high nAb titers against BA.1 and novel sublineages if collected up to 6 months since last event (either vaccine dose or infection). These Omicron neutralizing levels are comparable in dilutional titers to that of WA-1 CCP neutralizing WA-1, but their prevalence is much higher at this time, facilitating recruitment of suitable donors. Pre-Omicron CCP boosted with WA-1-type vaccines induces heterologous immunity that effectively neutralizes Omicron in the same assays which rule in or out therapeutic anti-Spike monoclonal antibodies. Consequently, prescreening of Vax-CCP donors for nAb titers is not necessary, and qualification of Vax-CCP units remains advisable only within clinical trials. A more objective way to assess previous infection (convalescence) would be by measuring anti-nucleocapsid (N) antibodies, but unfortunately these vanish quickly [36, 37]. Previous symptomatic infection and vaccination can be established by collecting past medical history (PMH) during the donor selection visit, which is cheaper, faster, and more reliable than measuring rapidly

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

declining anti-N antibodies. Although there is no formal evidence for this, it is likely that asymptomatic infection (leading to lower nAb levels in pre-Omicron studies) also leads to lower nAb levels after vaccination compared to symptomatic infection, given that disease severity correlates with nAb titer [38, 39]: hence asymptomatically infected donors missed by investigating PMH are also less likely to be useful.

The same reasoning applies to uninfected vaccinees receiving third dose boosts, but several authorities, including the FDA, do not currently allow collection from such donors for CCP therapy on the basis that the convalescent polyclonal and poly-target response is a prerequisite for efficacy and superior to the polyclonal anti-Spike-only response induced by vaccines. This may be a false premise for recipients of inactivated whole-virus vaccines (e.g., BBIBP-CorV or VLA2001): for BBIBP-CorV, where efficacy against Omicron is largely reduced [18, 20, 40], but the impact of boost doses is still unreported at the time of writing. Table 1 and Table 9 clearly show that 3-doses of BNT162b2 are enough to restore nAb levels against Omicron in the absence of SARS-CoV-2 infection.

Another point to consider is that information on nAb levels after the third vaccine dose has been almost exclusively investigated for only 1 month of follow-up, while studies on convalescents extend to more than 6 months. At present, it seems hence advisable to start from convalescent vaccinees rather than uninfected 3-dose vaccinees. This is also confirmed by immune escape reported *in vivo* after usage of vaccine (non-convalescent) plasma [41] despite very high nAb titres, likely due to restricted antigen specificity. Vaccine schedules with a delayed boost seem to elicit higher and broader nAb levels than the approved, short schedules[42, 43, 44, 45], but this remain to be confirmed in larger series. The same is true for breakthrough infections from Alpha or Delta VOC in fully BNT162b2 vaccinated subjects[46], although variation in time from infection due to successive waves is a major confounder.

With the increase of Omicron seroprevalence in time, polyclonal intravenous immunoglobulins collected from regular donors could become a more standardized alternative to CCP, but their efficacy to date (at the peak of the vaccination campaign) is still 16-fold reduced against Omicron compared to wild-type SARS-CoV-2[47], and such preparations include only IgG and not IgM and IgA, which have powerful SARS-CoV-2 activity [48, 49]. Nevertheless, the FDA recently reported efficacy of hyperimmune serum against BA.1, BA.2, BA.3, BA.2.12.1, and BA.4/5 [50].

CCP collection from vaccinated convalescents (regardless of infecting sublineage, vaccine type and number of doses) is likely to achieve high nAb titer against VOC Omicron, and, on the basis of lessons learnt with CCP usage during the first 2 years of the pandemic. Although in ideal situations one would prefer RCT evidence of efficacy against Omicron before deployment, there is concern that variants are generated so rapidly that by the time such trials commence this variant could be replaced by another. Given the success of CCP in 2 outpatient RCTs in reducing disease progression or hospitalization[6, 7] and the loss of major mAb therapies due to Omicron antigenic changes, the high titers in 2022 omicron CCP collected from vaccinated convalescents provides an immediate option for COVID-19, especially in LMIC. Given the reduced hospitalization rate with Omicron compared to Delta [51], it is even more relevant to identify patient subsets at risk of progression in order to minimize the number needed to treat to prevent a single hospitalization. Using the same indications for use of mAb therapies while using the same (now unused) in-hospital facilities seems a logical approach.

We declare we have no conflict of interest related to this manuscript.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

1. Ahmed SF, Quadeer AA, McKay M. SARS-CoV-2 T cell responses are expected to remain robust against Omicron. *Viruses* **14**, 79 (2022).

2. Bernasconi A*, et al.* Report on Omicron Spike mutations on epitopes and immunological/epidemiological/kinetics effects from literature. Accessed at https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770 on July 23, 2022.) (2021).

3. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. *Lancet Infect Dis*, (2022).

4. Zhou S*, et al.* β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. *The Journal of Infectious Diseases* **224**, 415-419 (2021).

5. Jayk Bernal A*, et al.* Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med* **386**, 509-520 (2022).

6. Libster R*, et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med* **384**, 610-618 (2021).

7. Sullivan D*, et al.* Early Outpatient Treatment for Covid-19 with Convalescent Plasma. *N Engl J Med*, (2021).

8. Vickers MA*, et al.* Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors. *Transfusion* **61**, 2099-2106 (2021).

9. Schmidt F*, et al.* High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. *Nature* **600**, 512-516 (2021).

10. Di Germanio C*, et al.* Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing Antibodies Against SARS-CoV-2 Variants. *Transfusion* **62**, 563-569 (2021).

11. Munro APS*, et al.* Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *The Lancet* **398**, 2258-2276 (2021).

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

12. Franchini M, *et al.* Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors. *Transfusion* **62**, 1171-1176 (2022).

13. Jacobsen H, *et al.* Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. 2021.2012.2021.21267898 (2021).

14. Planas D, *et al.* Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature* **602**, 671-675 (2022).

15. Bekliz M, *et al.* Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through homologous and heterologous variants. 2021.2012.2028.21268491 (2021).

16. Rossler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. *N Engl J Med* **386**, 698-700 (2022).

17. Muik A, *et al.* Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. *Science* **375**, 678-680 (2022).

18. Zhao X, *et al.* Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescents. 2021.2012.2016.472391 (2021).

19. Dolzhikova IV, *et al.* Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant. 2021.2012.2017.21267976 (2021).

20. Bowen JE, *et al.* Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines. 2022.2003.2015.484542 (2022).

21. Carazo S, *et al.* Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination. 2022.2004.2029.22274455 (2022).

22. Turelli P, *et al.* Omicron infection induces low-level, narrow-range SARS-CoV-2 neutralizing activity. 2022.2005.2002.22274436 (2022).

23. Qu P, *et al.* Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. *N Engl J Med* **386**, 2526-2528 (2022).

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

24. Richardson SI, *et al.* SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1. 2022.2007.2014.500039 (2022).

25. Zhou R, *et al.* Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits broadly cross-reactive immune responses. *Clin Transl Med* **2**, e720 (2022).

26. Aggarwal A, *et al.* SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. 2022.2007.2007.22277128 (2022).

27. Jian F, *et al.* Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants. 2022.2008.2009.503384 (2022).

28. Xie X, Zou J, Kurhade C, Liu M, Ren P, Shi P-Y. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine. 2022.2007.2029.502055 (2022).

29. Khoury DS, *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021).

30. Feng S, *et al.* Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nature Medicine* **27**, 2032-2040 (2021).

31. Gilbert PB, *et al.* Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science*, eab3435 (2021).

32. Earle KA, *et al.* Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* **39**, 4423-4428 (2021).

33. Tyrrell DA. Neutralization of viruses by homologous immune serum. II. Theoretical study of the equilibrium state. *The Journal of experimental medicine* **97**, 863-870 (1953).

34. Andreano E, *et al.* COVID-19 mRNA third dose induces a unique hybrid immunity-like antibody response. 2022.2005.2009.491201 (2022).

35. Ryan KA, *et al.* Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant. 2021.2012.2024.474081 (2021).

36. Krutikov M, *et al.* Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

pandemic (VIVALDI study): prospective cohort study in England. *The Lancet Healthy Longevity*, (2021).

37. Amjadi MF, *et al.* Anti-membrane and anti-spike antibodies are long-lasting and together discriminate between past COVID-19 infection and vaccination. 2021.2011.2002.21265750 (2021).

38. Klein S, *et al.* Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. *J Clin Invest* **130**, 6141-6150 (2020).

39. Focosi D, Franchini M. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. *European journal of haematology* **107**, 24-28 (2021).

40. Yu X, *et al.* Pseudotyped SARS-CoV-2 Omicron variant exhibits significant escape from neutralization induced by a third booster dose of vaccination. 2021.2012.2017.21267961 (2021).

41. Gachoud D, *et al.* Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents. 2022.2004.2024.22274200 (2022).

42. Chatterjee D, *et al.* SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. *Cell Rep* **38**, 110429 (2022).

43. Grunau B, *et al.* Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals. *JAMA* **327**, 279-281 (2022).

44. Tauzin A, *et al.* A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. *medRxiv [Preprint]*, 2021.2003.2018.435972 (2021).

45. Skowronski DM, *et al.* Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. *Clin Infect Dis*, ciac290 (2022).

46. Miyamoto S, *et al.* Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. 2021.2012.2028.21268481 (2022).

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

47. Focosi D, Franchini M. Passive immunotherapies for COVID-19: The subtle line between standard and hyperimmune immunoglobulins is getting invisible. *Reviews in medical virology*, e2341 (2022).

48. Klingler J*, et al.* Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *J Infect Dis* **223**, 957-970 (2020).

49. Wang Z*, et al.* Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Sci Transl Med*, (2020).

50. Awasthi M, Golding H, Khurana S. SARS-CoV-2 hyperimmune intravenous human immunoglobulins neutralizes Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.3 and BA.4/BA.5 for treatment of COVID-19. *Clinical Infectious Diseases*, (2022).

51. Wolter N*, et al.* Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa. *Lancet* **399**, 437-446 (2022).

52. Zeng C*, et al.* Neutralization and Stability of SARS-CoV-2 Omicron Variant. *bioRxiv*, (2021).

53. Liu L*, et al.* Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. *Nature* **602**, 676-681 (2022).

54. Schmidt F*, et al.* Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *N Engl J Med* **386**, 599-601 (2022).

55. Arien KK*, et al.* Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. *NPJ Vaccines* **7**, 35 (2022).

56. Lusvarghi S*, et al.* SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies. *Sci Transl Med*, eabn8543 (2022).

57. Hoffmann M*, et al.* The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. *Cell* **185**, 447-456 e411 (2022).

58. Zou J*, et al.* Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. *Nat Commun* **13**, 852 (2022).

59. Zhang L*, et al.* The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. *Emerg Microbes Infect* **11**, 1-5 (2022).

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

60. Gruell H, *et al.* mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. *Nat Med* **28**, 477-480 (2022).

61. Dejnirattisai W, *et al.* SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. *Cell* **185**, 467-484 e415 (2022).

62. Sheward DJ, *et al.* Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron). *bioRxiv*, 2021.2012.2019.473354 (2021).

63. Tada T, *et al.* Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. *EBioMedicine* **78**, 103944 (2022).

64. Aggarwal A, *et al.* SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. *medRxiv*, 2021.2012.2014.21267772 (2021).

65. Zhao X, *et al.* Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. *N Engl J Med* **386**, 894-896 (2022).

66. Bowen JE, *et al.* Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines. *bioRxiv*, (2022).

67. Carreno JM, *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. *Nature* **602**, 682-688 (2022).

68. Syed AM, *et al.* Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. *medRxiv*, (2022).

69. Haveri A, *et al.* Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. *Eur J Immunol*, (2022).

70. Li M, *et al.* Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. *Blood Adv*, 2022.2003.2001.22271662 (2022).

71. Kurahashi Y, *et al.* Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination. *medRxiv*, 2022.2002.2024.22271262 (2022).

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

72. Lechmere T, *et al.* Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. *mBio* **13**, e0379821 (2022).

73. Edara VV, *et al.* mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. *Cell Rep Med* **3**, 100529 (2022).

74. Cele S, *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature* **602**, 654-656 (2022).

75. Wilhelm A, *et al.* Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies. *medRxiv*, 2021.2012.2007.21267432 (2021).

76. Doria-Rose NA, *et al.* Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization. *medRxiv*, 2021.2012.2015.21267805 (2021).

77. Kawaoka Y, *et al.* Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. *Res Sq*, (2022).

78. Dejnirattisai W, *et al.* Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. *Lancet* **399**, 234-236 (2022).

79. Wang Q, *et al.* Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. *Nature*, (2022).

80. Khan K, *et al.* Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. *Nat Commun* **13**, 4686 (2022).

81. Muik A, *et al.* Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5. 2022.2008.2002.502461 (2022).

82. Planas D, *et al.* Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection. 2022.2007.2022.22277885 (2022).

83. Yu J, *et al.* Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. 2022.2002.2006.22270533 (2022).

84. Tuekprakhon A, *et al.* Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. *Cell* **185**, 2422-2433.e2413 (2022).

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

85. Hachmann NP*, et al.* Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1 and BA.4/BA.5. *N Engl J Med* **387**, 86-88 (2022).

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1

PRISMA flowchart for the current study.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2

Geometric mean neutralizing titers (GMT_{50}) against WA-1 versus Omicron BA.1 by study for A) unvaccinated convalescent plasma and B) vaccinated plasma with or without COVID-19. Geomeans for entire study groups with neutralization of WA-1 in filled circles and of Omicron BA.1 in empty circles with geomeans, fold reduction (FR) above data, and number of studies above x-axis. All geomeans are not statistically significant in difference by multiple comparison in Tukey's test.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 3

Percent of individual plasma samples in each study showing any titer of Omicron BA.1 neutralization. The percent of samples within a study condition which neutralized Omicron BA.1 graphed in increasing percentages with the number of samples tested on the right y axis. A) pre-Alpha CCP neutralization of Omicron BA.1; B) Alpha, Beta and Delta CCP neutralization of Omicron BA.1 C) 2 dose mRNA vaccines neutralization of Omicron BA.1 D) post-COVID-19/post-vaccine (Vax-CCP) and uninfected 3-dose vaccine neutralization of Omicron BA.1.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 4

Geometric mean neutralizing titers (GMT_{50}) of anti-WA.1 or anti-Omicron BA.1 neutralizing antibodies in plasma samples from 5 studies investigating diverse SARS-CoV-2 infecting lineage or vaccination status. 5 studies characterized A) pre-Alpha, Alpha, Beta and Delta CCP for Omicron BA.1 nAb compared to WA-1, and also B) 2 or 3 doses BNT162b plasma, as well as post-COVID-19 plus BNT162b vaccine (Vax-CCP). C) 9 additional studies looked at the same vaccine conditions in the first 5 comparing WA-1 nAb to Omicron BA.1 nAb.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 5

Geometric mean neutralizing titers (GMT_{50}) against WA-1 versus Omicron BA.1, BA.2 or BA.4/5 for A) boosted vaccinated plasma with or without BA.1 COVID-19 and B) unvaccinated preomicron or BA.1 CCP. Geomeans for entire study groups with neutralization of WA-1 in filled circles with Omicron in empty circles with geomeans and fold reduction (FR) above data and number of studies above x-axis. All geomeans are not statistically significant in difference by multiple comparison in Tukey's test. The percent of samples within a study condition which neutralized Omicron graphed in increasing percentages with the number of samples tested on the right y axis. C) uninfected 3-dose vaccine neutralization of Omicron BA.1, BA.2 and BA.4/5.; D) post-COVID-19-BA.1/post-vaccine (Vax-CCP).



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 6

GMT_{50} from each study with minimum and maximum dilution titer also shown. Live virus assays are on the left and pseudoviral assays on the right. A) pre-alpha CCP against WA-1, B) post COVID-19/Vax against WA-1. C) 3 dose BNT 162b2 against WA-1, D) post COVID-19 BA.1/Vac against WA-1, E) pre-alpha CCP against omicron BA.1, F) post COVID-19/Vax against Omicron BA.1. G) 3 dose BNT 162b2 against Omicron BA.1, H) post COVID-19 BA.1/Vac against Omicron BA.1, I) post COVID-19 BA.1/Vac against Omicron BA.2 J) post COVID-19 BA.1/Vac against BA.4/5.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1

Comparison of WA-1 to Omicron BA.1 nAb and percent with any Omicron BA.1 nAb amongst VOC CCP and vaccination status.

plasma type	number of studies	WA-1 nAb GMT_{50}	Omicron BA1 nAb GMT_{50}	fold reduction in nAb GMT_{50} vs. Omicron BA.1	total number individuals in all studies	total Omicron BA.1 neutralizing number	Omicron BA.1 neutralizing percent
pre-Alpha	27	311	15	20	707	315	45
Alpha	6	301	6	50	64	21	33
Beta	5	91	8	11	37	19	51
Delta	7	464	42	11	94	69	73
2 dose BNT162b2 plasma	22	628	27	24	432	202	47
2 dose mRNA-1273 plasma	9	686	20	35	134	81	60
post-COVID-19/full vacc plasma	19	2753	192	14	279	243	87
3 dose BNT162b2 plasma	17	2588	290	9	310	286	92

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2

Efficacy of CCP, vaccinee plasma and Vax-CCP expressed as GMT_{50} against Omicron sublineages.

plasma type	number of studies	WA-1 nAb GMT_{50}	Omicron BA.1 nAb GMT_{50} (Fold reduction from WA-1)	Omicron BA.2 nAb GMT_{50} (Fold reduction from WA-1)	Omicron BA.14/5 nAb GMT_{50} (Fold reduction from WA-1)	total number individuals in all studies	Omicron BA.1; BA.2; BA.4/5 neutralizing percent
Pre-omicron CCP	3	1338	133 (10 FR)	132 (10 FR)	177 (8 FR)	50	35; 37;40
BA.1 CCP	3	71	366 (0.16 FR)	180 (0.4 FR)	82 (1 FR)	74	66; 80; 76
BA.4/5 CCP	1	904	557 (2 FR)	884 (1 FR)	1047 (1 FR)	13	100; 100; 100
3 dose BNT162b2 plasma	8	3247	494 (7 FR)	511 (6 FR)	189 (16 FR)	159	97; 98; 96
post-COVID-19-BA.1/full vacc plasma	11	3578	1713 (2 FR)	1830 (2 FR)	454 (8 FR)	142	99; 99; 99

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 1

Synopsis of 27 *in vitro* studies investigating the efficacy of pre-Alpha CCP against Omicron

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(pre-Alpha CCP) WA-1 GMT_{50}	(pre-Alpha CCP) BA.1 GMT_{50}	(pre-Alpha CCP) fold drop vs. BA.1	(pre-Alpha CCP) number in study	(pre-Alpha CCP) BA.1 neutralizing number	(pre-Alpha CCP) BA.1 neutralizing percent
Zeng[52]	2	(1-2) mo	1712	14	122	9	1	11
Liu[53]	2	(9-120) days	4344	135	32	10	2	20
Schmidt[54]	2	1.2 mo	2616	68	38	20	19	95
Schmidt[54]	2	12 mo	2037	136	15	20	17	85
Schmidt[54]	2	6 mo	1678	34	49	20	13	65
Arien[55]	1	1 mo	1086	50	22	10	1	10
Lusvarghi[56]	2	30 (14-51) days	715	25	29	16	2	13
Hoffman[57]	2	< 2 mo	614	8	77	17	8	47
Zou[58]	1	1 mo	601	38	16	64	41	64
Planas[14]	2	6 mo	569	28	20	16	6	38
Planas[14]	2	12 mo	580	29	20	23	8	35
Zhang[59]	2	(1-3) mo	556	66	8	28	28	100
Gruell[60]	2	1.5 mo	494	6	82	30	3	10
Gruell[60]	2	12 mo	93	8	12	30	9	30
Dejnirattisai[61]	1	42 med days	475	28	17	32	32	100
Sheward[62]	2	1 mo	350	40	9	34	25	74
Tada[63]	2	(32-57)	233	9	26	10	4	40
Aggerwal[64]	1	1+ mo	215	10	22	20	0	0
Zhao[65]	2	18 (11-51) days	193	11	17	16	1	6
Bowen[66]	2	(28-78) days	162	10	16	28	13	46
Zou[58]	1	6 mo	142	32	4	36	30	83
Carreno[67]	1	58 (23-87) days	67	6	11	15	4	27
Syed[68]	2	<1 mo	80	20	4	8	6	75
Bekliz[15]	1	(3-137) days	37	1	45	34	5	15
Haveri[69]	1	1 mo	32	2	16	13	0	0
Li[70]	1	<1 mo	28	2	14	108	22	22
Kurahashi[71]	1	(1-3) mo	19	2	13	40	15	38
GM (GMT_{50})			1712	15	20			
Total (AVG%)						707	315	(45%)

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 2

Synopsis of 5 *in vitro* studies investigating the efficacy of Alpha CCP against Omicron

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(Alpha CCP) WA-1 GMT_{50}	(Alpha CCP) BA.1 GMT_{50}	(Alpha CCP) fold reduction vs. BA.1	(Alpha CCP) number	(Alpha CCP) BA.1 neutralizing number	(Alpha CCP) BA.1 neutralizing percent
Lusvarghi[56]	2	30 (14-51) days	4978	30	166	4	1	25
Dejnirattisai[61]	1	19 med days	1313	39	34	18	18	100
Rossler[16]	1		256	4	63	10	0	0
Haveri[69]	1	1 mo	32	2	16	20	0	0
Bekliz[15]	1	3-137 days	46	1	57	12	2	17
GM (GMT_{50})			301	6	50			
Total (AVG%)						64	21	(33%)

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 3

Synopsis of 5 *in vitro* studies investigating the efficacy of Beta CCP against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(beta CCP) WA-1 GMT_{50}	(beta CCP) BA.1 GMT_{50}	(beta CCP) fold reduction vs. BA.1	(beta CCP) number	(beta CCP) BA.1 neutralizing number	(beta CCP) BA.1 neutralizing percent
Lusvarghi[56]	2	30 (14-51) days	439	191	2	2	2	100
Dejnirattisai[61]	1	61 med days	327	28	12	14	14	100
Rossler[16]	1		128	4	32	8	1	13
Haveri[69]	1	1 mo	16	2	8	5	0	0
Bekliz[15]	1	3-137 days	21	1	23	8	2	25
GM (GMT_{50})			140	8	11			
Total (AVG%)						37	19	(51%)

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 4

Synopsis of 7 *in vitro* studies investigating the efficacy of Delta CCP against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(Delta CCP) WA-1 GMT_{50}	(Delta CCP) BA.1 GMT_{50}	(Delta CCP) fold drop vs. BA.1	(Delta CCP) number	(Delta CCP) BA.1 neutralizing number	(Delta CCP) BA.1 neutralizing percent
Zeng[52]	2	(1-2) mo	11200	3476	3	19	10	53
Lechmere[72]	2	(13-22) days	668	164	4	14	12	86
Lusvarghi[56]	2	30 (14-51) days	1211	18	66	15	12	80
Aggerwal[64]	1		770	37	21	10	9	90
Rossler[16]	1		192	8	25	7	1	14
Bekliz[15]	1	3-137 days	73	3	24	10	6	60
Dejnirattisai[61]	1	38 med dayas	47	27	2	19	19	100
GM (GMT_{50})			167	10	17			
Total (AVG%)						94	69	(73%)

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 5

Synopsis of 22 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 BNT162b2 doses against Omicron.

reference	Assay type (live virus =1 Pseudo virus=2)	time mean or median (min-max)	(2 dose BNT162 b2 plasma) WA-1 GMT_{50}	(2 dose BNT162 b2 plasma) BA.1 GMT_{50}	(2 dose BNT162 b2 plasma) fold reduction vs. BA.1	(2 dose BNT162 b2 plasma) number	(2 dose BNT162b 2 plasma) BA.1 neutralizing number	(2 dose BNT162b 2 plasma) BA.1 neutralizing percent
Schmidt[54]	2	1 mo	7627	92	83	18	15	83
Liu[53]	2	(16-213) days	4669	222	21	13	6	46
Zeng[52]	2	(21-28) days	2769	121	23	48	13	27
Schmidt[54]	2	5 mo	2435	126	19	18	15	83
Dejnirattisai[61]	1	1 mo	1993	19	105	20	20	100
Chatterjee[42]	2	4 mo	1544	935	2	25	25	100
Syed[68]	2	1-1.5 mo	1280	80	16	21	14	67
Tada[63]	2	90 days	859	25	34	9	7	78
Bowen[66]	2	9-20 days	764	28	27	10	9	90
Chatterjee[42]	2	1 mo	641	105	6	19	10	53
Hoffman[57]	2	<3 mo	604	10	60	11	1	9
Lusvarghi[56]	2	30 (28-34) days	562	22	26	39	3	8
Gruell[60]	2	1 mo	546	8	68	30	10	33
Rossler[16]	1	1 mo	512	24	21	20	9	45
Edara[73]	1	(14-28) days	384	20	19	13	2	15
Muik[17]	1	1 mo	368	6	61	25	8	32
Cele[74]	1	(10-48) days	263	12	22	8	5	83
Bekliz[15]	1	1 mo	338	4	86	16	11	69
Planas[14]	2	161 (138-176) days	329	30	11	16	1	6
Carreno[67]	1	18 (14-21) days	274	11	25	10	7	70
Gruell[60]	2	5 mo	139	9	15	30	11	37
Wilheim[75]	1	6 mo	6	1	6	15	0	0
GM (GMT_{50})			628	27	24			
Total (AVG%)						432	202	(47%)

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 6

Synopsis of 9 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 mRNA-1273 doses against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(2 dose mRNA-1273 plasma) WA-1 GMT_{50}	(2 dose mRNA-1273 plasma) BA.1 GMT_{50}	(2 dose mRNA-1273 plasma) fold drop vs. BA.1	(2 dose mRNA-1273 plasma) number	(2 dose mRNA-1273 plasma) BA.1 neutralizing number	(2 dose mRNA-1273 plasma) BA.1 neutralizing percent
Doria-Rose[76]	2	1 mo	3016	62	49	30	22	73
Syed[68]	2	1-1.5 mo	2560	320	8	10	8	80
Doria-Rose[76]	2	1 mo	2269	27	84	30	22	73
Bowen[66]	2	6-15 days	1155	26	44	11	9	82
Tada[63]	2	80 days	999	38	26	8	5	63
Edara[73]	1	1 mo	745	15	50	11	4	36
Carreno[67]	1	26 (14-36) days	581	14	42	10	10	100
Rossler[16]	1	5 mo	384	8	48	10	1	10
Wilheim[75]	1	6 mo	10	1	20	14	0	0
GM (GMT_{50})			644	21	31			
Total (AVG%)						134	81	(60%)

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 7

Synopsis of 17 *in vitro* studies investigating the efficacy of plasma from infected and vaccinated (2 BNT162b2 doses) subjects (Vax-CCP) against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(post-COVID-19/full vacc plasma) WA-1 GMT_{50}	(post-COVID-19/full vacc plasma) BA.1 GMT_{50}	(post-COVID-19/full vacc plasma) fold drop vs. BA.1	(post-COVID-19/full vacc plasma) number	(post-COVID-19/full vacc plasma) BA.1 neutralizing number	(post-COVID-19/full vacc plasma) BA.1 neutralizing percent
Schmidt[54]	2	1 mo	388872	8106	48	17	17	100
Planas[14]	2	32 (21-48) days	78162	1475	53	22	22	100
Tada[63]	2	1 mo	14868	921	16	7	7	100
Cele[74]	1	(18-63)	6763	305	22	13	13	100
Kawoaka[77]	1	1 mo	10002	2029	5	13	13	100
Kawoaka[77]	1	3 mo	2251	399	6	13	13	100
Gruell[60]	2	1.5 mo	7997	1599	5	30	30	100
Arien[55]	1		4822	236	20	10	10	100
Carreno[67]	1	26 (15-39) days	2000	146	14	10	10	100
Dejnirattisai[61]	1	1 mo	1899	215	9	17	17	100
Li[70]	1	< 1 mo	1598	80	20	20	20	100
Bekliz[15]	1	1 mo	1190	65	18	6	6	100
Haveri[69]	1	1 mo	1024	32	32	33	33	100
Rossler[16]	1		1024	256	4	5	5	100
Edara[73]	1	6 mo	625	31	20	24	15	63
Kurahashi[71]	1	1 mo	21	2	14	19	7	37
Wilheim[75]	1	(.07-7.6) mo	100	10	10	20	5	25
GM (GMT_{50})			2753	192	14			
Total (AVG%)						279	243	(87%)

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 8

Synopsis of 17 *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with 3 BNT162b2 doses against Omicron.

reference	Assay type (live virus =1 Pseudovirus=2)	time mean or median (min-max)	(3 dose BNT162b2 plasma) WA-1 GMT_{50}	(3 dose BNT162b2 plasma) BA.1 GMT_{50}	(3 dose BNT162b2 plasma) fold drop vs. BA.1	(3 dose BNT162b2 plasma) number	(3 dose BNT162b2 plasma) BA.1 neutralizing number	(3 dose BNT162b2 plasma) BA.1 neutralizing percent
Schmidt[54]	2	1 mo	65617	3871	17	18	18	100
Planas[14]	2	33 (8-61) days	12739	722	18	20	20	100
Zeng[52]	2	(21-28) days	10412	3179	3	23	20	87
Dejnirattisai[61]	1	1 mo	9219	649	14	20	20	100
Gruell[60]	2	1 mo	6241	1248	5	30	30	100
Lusvarghi[56]	2	43 (7-93) days	5029	718	7	39	39	100
Tada[63]	2	1 mo	4892	360	14	12	12	100
Liu[53]	2	(14-90) days	4673	715	7	15	15	100
Kawoaka[77]	1	1 mo	2866	485	6	10	10	100
Arien[55]	1		2157	165	13	10	10	100
Hoffman[57]	2	<1 mo	2006	305	7	10	9	90
Edara[73]	1	(]7-28) days	1247	89	14	35	31	89
Carreno[67]	1	19 (14-28) days	710	94	8	10	10	100
Syed[68]	2	1-1.5 mo	960	160	6	8	8	100
Muik[17]	1	1 mo	673	106	6	28	27	96
Haveri[69]	1	(21–42) days	256	16	16	7	7	100
Wilheim[75]	1	3 mo	100	10	10	15	0	0
GM (GMT_{50})		time mean or median (min-max)	2588	290	9			
Total (AVG%)						310	286	(92%)

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 9

Synopsis of *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with 3 doses of mRNA-1273, AZD-1222 or Ad26.COV2 against BA.1. Because of diversity of vaccines the geomeans and sums were not computed.

reference	vaccine type	WA-1 GMT_{50}	fold drop vs. BA.1	BA.1 GMT_{50}	number	BA.1 neutralizing number	BA.1 neutralizing percent
Careno[67]	COVID19 + mRNA-1273	3000	11	272	10	10	100
Edara[73]	COVID19 + mRNA-1273 6 mo	931	25	38	13	9	69
Careno[67]	3 dose mRNA-1273	1000	17	60	10	10	100
Doria-Rose[76]	3 dose mRNA-1273	8457	4	2002	30	30	100
Doria-Rose[76]	3 dose mRNA-1273	4216	6	650	30	30	100
Edara[73]	3 dose mRNA-1273	1395	15	96	17	16	94
Dejnirattisai[78]	AZD1222	390	19	21	41	41	100
Rossler[16]	AZD1222	250	25	10.0	20	0	0
Planas[14]	AZD1222 5 mo	187	18	10	18	2	10
Syed[68]	Ad26.COV2	28	1	20.0	9	2	22
Schmidt[54]	Ad26.COV2 1 mo	588	24	25	19	2	11
Schmidt[54]	Ad26.COV2 6 mo	982	23	43	19	11	58

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 10

Synopsis of *in vitro* studies investigating the efficacy of plasma from (pre-omicron, BA.1 and BA.4/5 CCP) subjects against Omicron BA.1, BA.2 and BA.4/5.

reference	Assay type (live virus =1 Pseudovirus =2)	time mean or median (min-max)	WA-1 nAb GMT_{50}	Omicron BA.1 nAb GMT_{50} (Fold reduction from WA-1)	Omicron BA.2 nAb GMT_{50} (Fold reduction from WA-1)	Omicron BA.14/5 nAb GMT_{50} (Fold reduction from WA-1)	Number in study	BA.1; BA.2; BA.4/5 neutralizing number	BA.1; BA.2; BA.4/5 neutralizing percent
preomicron									
Wang[79]	1	(7-213) days	5185	845 (6 FR)	939 (6 FR)	596 (9 FR)	22	22; 22;22	100;100; 100
Awasthi[50]	2	>1 mo	130	13 (10 FR)	12 (11 FR)	13 (13 FR)	10	1; 1; 1	10; 10; 10
Qu[23]	2	3 day post hosp.	3554	214 (17 FR)	205	717 (5 FR)	18	12; 14; 17	67; 78; 94
GM (GMT_{50})			1338	133 (10 FR)	132 (10 FR)	177 (8 FR)			
Total (AVG%)							50	35; 37;40	(70;74; 80)
BA.1									
Khan[80]	1	23 (19-27iqr)	Not done	275	Not done	36	24	24; nd; 18	100;nd; 75
Zou[58]	1	25 (13-62) days	16	445 (0.04 FR)	107 (0.15 FR	Not done	20	20; 19; nd	100;95; nd
Qu[23]	2	1-8 days post hosp.	317	399 (0.8 FR)	304 (1.04 FR)	189 (2 FR)	30	22; 21; 23	73;70;77
GM (GMT_{50})			71	366 (0.16 FR)	180 (0.4 FR)	82 (1 FR)	74		
Total (AVG%)								66;40;41	89;80;93
BA.4/5									
Richardson[24]	2	< 9 days into hosp.	904	557 (2 FR)	884 (1 FR)	1047 (1 FR)	13	13;13;13	100;100; 100

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 11

Synopsis of *in vitro* studies investigating the efficacy of plasma from (post-COVID-19-BA.1/full vacc plasma) subjects (Vax-CCP) against Omicron BA.1, BA.2 and BA.4/5.

reference	Assay type (live virus =1 Pseudovirus= 2)	time mean or median (min-max)	WA-1 nAb GMT_{50}	Omicron BA.1 nAb GMT_{50} (Fold reduction from WA-1)	Omicron BA.2 nAb GMT_{50} (Fold reduction from WA-1)	Omicron BA.14/5 nAb GMT_{50} (Fold reduction from WA-1)	Number in study	BA.1; BA.2; BA.4/5 neutralizing number	BA.1; BA.2; BA.4/5 neutralizing percent
Muik[81] (BA.1)	1	43 (25-55)	780	656 (1 FR)	800 (1 FR)	156 (5 FR)	14	14;14;13	100;100;93
Muik[81] (BA.2)	1	39 (30-99)	531	347 (2 FR)	545 (1 FR)	209 (3 FR)	13	13;13;13	100;100;100
Khan[80]	1		2038	507 (4 FR)		158 (13 FR)	15	15;nd;15	100;nd;100
Wang [79] (BA.1)	1	(14-135) days	9500	2406 (4 FR)	2052 (5 FR)	473 (20 FR)	13	13;13;13	100;100;100
Wang[79] (BA.2)	1	(14-36) days	9527	3054 (3 FR)	3679 (3 FR)	1627 (6 FR)	12	12;12;12	100;100;100
Planas[82]	1	80 med days	10000	7000 (1 FR)	9000 (1 FR)	1000 (10 R)	11	11;11;11	100;100;100
Awasthi[50]	2	>1 mo	1120	733 (2 FR)	380 (3 FR)	76 (15 FR)	6	6;6;6	100;100;100
Yu[83]	2	14 med days	4046	3249 (1 FR)	2448 (2 FR)		8	7;7;nd	88;88;nd
Richardson[24]	2	< 9 days into hosp.	5484	4244 (1 FR)	3779 (1 FR)	1984 (3 FR)	9	9;9;9	100;100;100
Tuekprakhon[84]	2	45 med days	5861	3563 (2 FR)	2119 (3 FR)	1064 (6 FR)	14	14;14;14	100;100;100
Hachman[85]	2	29 (2-113) days	11050	1740 (6 FR)	1910 (6 FR)	590 (19 (FR)	27	27;27;27	100;100;100
GM (GMT_{50})			3578	1713 (2 FR)	1830 (2 FR)	454 (8 FR)			
Total (AVG%)							142	141;126;133	99;99;99

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary table 12

Synopsis of *in vitro* studies investigating the efficacy of plasma from (3 dose BNT162b2 plasma) subjects against Omicron BA.1, BA.2 and BA.4/5.

reference	Assay type (live virus =1 Pseudovirus= 2)	time mean or median (min-max)	WA-1 nAb GMT_{50}	Omicron BA.1 nAb GMT_{50} (Fold reduction from WA-1)	Omicron BA.2 nAb GMT_{50} (Fold reduction from WA-1)	Omicron BA.14/5 nAb GMT_{50} (Fold reduction from WA-1)	Number in study	BA.1; BA.2; BA.4/5 neutralizing number	BA.1; BA.2; BA.4/5 neutralizing percent
Planas[82]	1	132 med days	2000	140 (14 FR)	100 (20 FR)	50 (40 FR)	22	19;20;19	86;91;86
Muik[81]	1	28 (26-30)	549	90 (6 FR)	93 (6 FR)	37 (15 FR)	18	17;18; 17	94;100;94
Khan[80]	1		4123	208 (20 FR)	Not done	211 (20 FR)	18	18;nd;;18	100;nd; 100
Wang[79]	1	(14-90) days	6657	130 (5 FR)0	1461 (5 FR)	347 (19 FR)	16	16;16;14	100;100; 88
Qu[23]	2	(21-28) days	2633	976 (3 FR)	933 (3 FR)	647 (4 FR)	15	14;14;15	93;93; 100
Tuekprakhon[84]	2	28 days	4122	1116 (4 FR)	1113 (4 FR)	360 (11 FR)	19	19;19;19	100;100; 100
Hachman[85]	2	14 days	5783	900 (6 FR)	829 (7 FR)	275 (21 FR)	27	27;27;27	100;100; 100
Yu[83]	2	14 days	6539	1066 (6 FR)	776 (8 FR)	Not done	24	24;24	100;100; nd
GM (GMT_{50})			3247	494 (7 FR)	511 (6 FR)	189 (16 FR)	1		
Total (AVG%)							159	154;138;129	97;98;96

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 1

Alternative graphing of Supplementary table 1 and Figure 2A. 27 *in vitro* studies investigating the efficacy of pre-Alpha CCP against Omicron with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 2

Alternative graphing of Supplementary table 2 and Figure 2A. 5 *in vitro* studies investigating the efficacy of Alpha CCP against Omicron with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 3

Alternative graphing of Supplementary table 3 and Figure 2A. 5 *in vitro* studies investigating the efficacy of Beta CCP against Omicron with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 4

Alternative graphing of Supplementary table 4 and Figure 2A. 7 *in vitro* studies investigating the efficacy of Delta CCP against Omicron with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 5

Alternative graphing of Supplementary table 5 and Figure 2B. 22 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 BNT162b2 doses against Omicron with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 6

Alternative graphing of Supplementary table 6 and Figure 2B. 9 *in vitro* studies investigating the efficacy of plasma from uninfected recipients of 2 mRNA-1273 doses against Omicron with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 7

Alternative graphing of Supplementary table 7 and Figure 2B. 17 *in vitro* studies investigating the efficacy of plasma from infected and vaccinated (2 BNT162b2 doses) subjects (VaxCCP) against Omicron with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 8

Alternative graphing of Supplementary table 8 and Figure 2B. 17 *in vitro* studies investigating the efficacy of plasma from uninfected subjects vaccinated with 3 BNT162b2 doses against Omicron with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 9

Alternative graphing of Supplementary table 10 and Figure 5. 7 *in vitro* studies investigating the efficacy of plasma from (pre-omicron, BA.1 and BA.4/5 CCP) subjects (VaxCCP) against Omicron BA.1, BA.2 and BA.4/5 with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.



medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 10

Alternative graphing of Supplement table 11 and Figure 5. 9 *in vitro* studies investigating the efficacy of plasma from (post-COVID-19-BA.1/full vacc plasma) subjects (VaxCCP) against Omicron BA.1, BA.2 and BA.4/5 with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



790

medRxiv preprint doi: https://doi.org/10.1101/2021.12.24.21268317; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figure 11

Alternative graphing of Supplementary table 12 and Figure 5. 8 *in vitro* studies investigating the efficacy of plasma from (3 dose BNT162b2 plasma) subjects (VaxCCP) against Omicron BA.1, BA.2 and BA.4/5 with GMT_{50} from each study with minimum and maximum dilution titer also shown. The absolute values are graphed in the upper panels for WA-1 on left and omicron on right. In the lower panels all numbers divided by the minimum value for each study to normalize for WA-1 on left and Omicron on right. The GMT_{50} approximates 10 with this computational division. Live virus assays are on the left and pseudoviral assays on the right.